During the last session, Taysha Gene Therapies Inc (NASDAQ:TSHA)’s traded shares were 1.61 million, with the beta value of the company hitting 0.39. At the end of the trading day, the stock’s price was $2.26, reflecting an intraday loss of -1.31% or -$0.03. The 52-week high for the TSHA share is $4.32, that puts it down -91.15 from that peak though still a striking 72.57% gain since the share price plummeted to a 52-week low of $0.62. The company’s market capitalization is $455.12M, and the average trade volume was 2.70 million shares over the past three months.
Taysha Gene Therapies Inc (TSHA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.09. TSHA has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Taysha Gene Therapies Inc (TSHA) registered a -1.31% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.31% in intraday trading to $2.26, hitting a weekly high. The stock’s 5-day price performance is -8.13%, and it has moved by -43.92% in 30 days. Based on these gigs, the overall price performance for the year is 222.86%.
The extremes of the forecast give a target low and a target high price of $7 and $44 respectively. As a result, TSHA is trading at a discount of -1846.9% off the target high and -209.73% off the low.
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
Statistics show that Taysha Gene Therapies Inc has outperformed its competitors in share price, compared to the industry in which it operates. Taysha Gene Therapies Inc (TSHA) shares have gone up 42.59% during the last six months, with a year-to-date growth rate more than the industry average at 57.29% against 12.30.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -137.69%. While earnings are projected to return 59.11% in 2024.
TSHA Dividends
Taysha Gene Therapies Inc is due to release its next quarterly earnings in August. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
